FTC Charges Seven Online Sellers
of Alternative Hormone Replacement Therapy with
Failing to Substantiate Products’ Health Claims

FTC News Release
October 5, 2007

The Federal Trade Commission today announced complaints against seven online sellers of alternative hormone replacement therapy (HRT) products, alleging that they made health claims for their natural progesterone creams without supporting scientific evidence. Six of the sellers have signed consent orders barring them from making such unsubstantiated claims in the future. The seventh did not respond to staff’s repeated contacts, and the case will now be heard by an administrative law judge.
“Millions of women seek safe, effective alternatives to hormone replacement therapy,” said Lydia Parnes, Director of the FTC’s Bureau of Consumer Protection. “These companies violated their trust by making claims they just couldn’t prove.”

The Commission’s Complaints

According to the FTC’s complaints, the respondents claimed that their natural progesterone creams: 1) are effective in preventing, treating, or curing osteoporosis; 2) are effective in preventing or reducing the risk of estrogen-induced endometrial (uterine) cancer; and 3) do not increase the user’s risk of developing breast cancer and/or are effective in preventing or reducing the user’s risk of developing breast cancer. The complaints allege the respondents did not have substantiation for these claims and, in some cases, misrepresented that clinical testing proved the products were effective.

The products allegedly sold without proper health-claim substantiation include: ProBalance and ProBalance Plus transdermal creams; Elation Therapy Natural Progesterone Cream; Preserve Progesterone Cream; Progesta Care Plus; EST progesterone cream; Restored Balance progesterone cream; Serenity for Women Natural Progesterone Cream; Nature’s Precise Cream; Eternal Woman Progesterone Cream; and Pro-Gest Body Cream.

The Consent Orders

The consent orders announced today settle the FTC’s charges against the following individuals and organizations: 1) Lawrence A. Jordan and Stephanie L. Jordan, individually and doing business as (d/b/a) Springboard and Pro Health Labs of Spring Valley, California; 2) Elation Therapy, Inc., and Robert Rutledge, individually and as an officer of Elation Therapy, Inc., of Marietta, Georgia; 3) Merilou Barnekow, individually and d/b/a Women’s Menopause Health Center of Surfside Beach, Texas; 4) The Green Willow Tree LLC, and Robert Burns individually and as a manager and member of The Green Willow Tree, LLC of Asheville, North Carolina; 5) Health Science International, Inc., and David Martin, individually and as an officer of Health Science International, Inc., of Port Orange, Florida; and 6) Shelly Black, individually and d/b/a Progesterone Advocates Network of Trabuco Canyon, California.

Under the terms of the orders, the respondents are required to have competent and reliable scientific evidence substantiating claims about the health benefits, performance, efficacy, safety, or side effects of any dietary supplement, food, drug, device, or health-related service or program, including claims that progesterone products are effective in mitigating, treating, preventing, or curing any disease. In addition, the orders prevent the respondents from misrepresenting the existence, contents, validity, results, conclusions, or interpretations of any test, study, or research. Finally, the orders contain record-keeping and notification provisions designed to ensure the respondents comply with their terms. The orders will expire in 20 years.
The charges against Herbs Nutrition Corporation and Syed M. Jafry, individually and as an officer of Herbs Nutrition Corporation of Torrance, California, have not been settled, and the case will be tried by an administrative law judge at the Commission.

Consumer Information

In the actions announced today, the FTC obtained all the relief necessary to protect consumers by focusing on some of the most egregious claims made by the online sellers of alternative HRT. The FTC staff is not aware of any competent and reliable scientific evidence to support claims that natural progesterone products are safe, or that they are effective in preventing osteoporosis, increasing bone density, or preventing, treating, or curing cancer, heart disease, or other diseases. When evaluating health-related claims for any product, it may be a good idea for consumers to talk to their primary care physician, pharmacist, or healthcare provider.

The Alternative HRT Web Surf

The FTC staff identified the respondents through an Internet search of Web sites advertising products that claimed they were natural alternatives to HRT and that they would prevent diseases such as cancer and osteoporosis. The FTC staff sent warning letters to 34 Web site operators informing them that they must have competent and reliable scientific evidence to support any health-related claims made for their products. The staff advised the marketers to revise or delete any false, misleading, or unsubstantiated claims.

The FTC’s letters noted that the staff was not aware of any competent and reliable scientific evidence to support claims that natural progesterone products are safe or are effective in preventing osteoporosis, increasing bone density, or preventing, treating, or curing cancer, heart disease, or other diseases. The U.S. Food and Drug Administration (FDA) sent letters to an additional 16 alternative HRT sellers, warning them that their business practices could be in violation of FDA law.

The FTC staff followed up with the online advertisers who received letters, and all except seven modified the claims on their Web sites. The Commission now has charged those seven sellers with violating the FTC Act, and has settled the charges against six of the seven sellers.

The Commission vote authorizing the filing of an administrative complaint against respondents Herbs Nutrition Corporation and Jafry was 5-0. The vote authorizing the filing of administrative complaints and consent orders settling the charges against the remaining respondents was 5-0. The consent orders will be subject to public comment for 30 days, beginning today and continuing through November 7, 2007, after which the Commission will consider whether to make them final. Comments should be send to: FTC Office of the Secretary, 600 Pennsylvania Ave., N.W., Washington, DC 20580.


Mitchell J. Katz,
Office of Public Affairs


Laura DeMartino
Bureau of Consumer Protection

Related Documents:

This page was posted on November 27, 2007.

Links to Recommended Companies

  • PharmacyChecker.com: Compare drug prices and save money at verified online pharmacies.
  • ConsumerLab.com: Evaluates the quality of dietary supplement and herbal products.
  • Amazon.com: Discount prices, huge inventory, and superb customer service.
  • OnlyMyEmail: Award-winning anti-spam services.
  • 10 Types: Website design, development, and hosting with superb technical support.